Automated closed-cell production platform solves dilemma of industrial-scale manufacturing for mesenchymal stromal cell-based therapy

• The ACISCP platform allows the suspension culture of clinical-grade MSCs. • The ACISCP platform enables the automatic harvesting of MSCs by enzymatic digestion of 3D TableTrix. • The MSCs produced using the ACISCP platform meet current quality standards of therapeutic cell products. • This system minimizes the limitations of monolayer culture and produces industrial-scale clinical-grade MSCs in one batch.